Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 [ID6261]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 8 May 2024
Molnupiravir for treating COVID-19 [ID6340]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 29 January 2025
Sipavibart for preventing COVID-19 [ID6282]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 February 2025
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology testsStatus:In developmentProgramme:Diagnostics guidanceExpected publication date: TBC
Remdesivir for treating COVID-19 [ID3808]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ensitrelvir for treating COVID-19 [ID6231]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sabizabulin for treating COVID-19 TS ID 11814Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vilobelimab for treating COVID-19 TS ID 11815Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
COVID-19 technology appraisal recommendations: surveillance and rapid update process statement consultationStatus:In developmentProgramme:NICE generalExpected publication date: TBC